Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cholesterol drug boosts immunotherapy against tough head and neck cancers

NCT ID NCT06636734

First seen Feb 16, 2026 · Last updated May 22, 2026 · Updated 9 times

Summary

This study tests whether adding a common cholesterol-lowering drug (lovastatin) to an immunotherapy (pembrolizumab) can help shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has not responded to prior treatments will receive both drugs. The goal is to see if the combination improves response rates and delays cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 HUMAN PAPILLOMAVIRUS-RELATED NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC LARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC NASOPHARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA METASTATIC ORAL CAVITY SQUAMOUS CELL CARCINOMA METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA METASTATIC PARANASAL SINUS SQUAMOUS CELL CARCINOMA RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT NASOPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT PARANASAL SINUS SQUAMOUS CELL CARCINOMA STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8 STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8 STAGE IV LARYNGEAL CANCER AJCC V8 STAGE IV LARYNGEAL CANCER AJCC V8 STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8 STAGE IV LIP AND ORAL CAVITY CANCER AJCC V8 STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 STAGE IV SINONASAL CANCER AJCC V8 STAGE IV SINONASAL CANCER AJCC V8